Loading clinical trials...
Loading clinical trials...
A Placebo-controlled, Double-blind Phase I Study in Healthy Volunteers With IMP761, a LAG-3 Agonist Antibody
Conditions
Interventions
IMP761
Placebo
+1 more
Locations
1
Netherlands
CHDR
Leiden, Netherlands
Start Date
July 17, 2024
Primary Completion Date
August 31, 2026
Completion Date
August 31, 2026
Last Updated
April 23, 2026
NCT07470866
NCT00104325
NCT07221448
NCT07388667
NCT07118891
NCT03878121
Lead Sponsor
Immutep S.A.S.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions